Scientific Committee

Jiayu Liao

Dr.Liao joined the University of California of Riverside as the founding faculty of the Bioengineering Department in 2006. Dr.Liao’s research at UCR has been focused on the development of novel high-sensitive and quantitative FRET(qFRET) technology platforms and Machine learning/Big Data for basic and translational research and development. Prior to this, Dr.Liao held joint appointments as a senior research fellow in Genomic Institute of Novartis Research Foundation (GNF) and the Scripps Research Institute(TSRI), where he analyzed the human genome and discovered the human sweet, and as the founding scientist of GPCR platform, where his research led to three marked drugs, Gilenya, siponimod and ocznimod